Literature DB >> 33665156

Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications.

Yongfeng Wang1, Ci Yin2, Lele Geng3, Weiyang Cai4.   

Abstract

The malignant phenotypes of cancer are defined not only by its intrinsic tumor cells but also by the tumor infiltrating immune cells (TIICs) recruited to the cancer microenvironment. Clear cell renal cell carcinoma (ccRCC) immune microenvironment plays an important role in the tumorigenesis. This research investigated the characteristics of immune cell invasion of renal cell carcinoma and provided clues for future clinical implementation. Retrospectively, ccRCC gene expression was analyzed with appropriate clinicopathological data from the Cancer Genome Atlas (TCGA) and GEO database up to December 2019. The CIBERSORT algorithm, meta-analysis, principal component analysis (PCA), Single-Sample Gene Set Enrichment Analysis (ssGSEA) and hierarchical agglomerative clustering were used to measure and evaluate the respective proportions of 22 cell types of immune infiltration using normalized gene expression data. We also focused on evaluating the association with TIICs subpopulations and clinical features and molecular subtypes. TIICs subpopulation, especially Macrophages subgroup, T follicular helper (Tfh) cells and CD8 T cells, all contribute to tumorigenesis. Unsupervised clustering analysis revealed that there existed two distinct TIICs subgroups with different survival patterns. TIICs are extensively involved in the pathogenesis and development of the ccRCC. Characterizing the composition of TIICs influences the metabolism of tumors, activity, level, stage, and survival of patients. Collectively, the TIIC analysis has the potential to assist in the assessment and selection of ccRCC prognosis and treatment.
Copyright © 2021 Wang, Yin, Geng and Cai.

Entities:  

Keywords:  CIBERSORT; TCGA; Tumor Microenvironment; clear cell renal cell carcinoma; tumor infiltrating immune cells

Year:  2021        PMID: 33665156      PMCID: PMC7923891          DOI: 10.3389/fonc.2020.491621

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  44 in total

Review 1.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Authors:  Spencer C Wei; Colm R Duffy; James P Allison
Journal:  Cancer Discov       Date:  2018-08-16       Impact factor: 39.397

2.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Authors:  Rico D Bense; Christos Sotiriou; Martine J Piccart-Gebhart; John B A G Haanen; Marcel A T M van Vugt; Elisabeth G E de Vries; Carolien P Schröder; Rudolf S N Fehrmann
Journal:  J Natl Cancer Inst       Date:  2016-10-13       Impact factor: 13.506

3.  Tumor-associated macrophage (TAM) infiltration in gastric cancer.

Authors:  Sumiya Ishigami; Shoji Natsugoe; Koki Tokuda; Akihiro Nakajo; Hiroshi Okumura; Masataka Matsumoto; Futoshi Miyazono; Shuichi Hokita; Takashi Aikou
Journal:  Anticancer Res       Date:  2003 Sep-Oct       Impact factor: 2.480

4.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

5.  Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer.

Authors:  Jae-Young Park; Ji-Youn Sung; Juhie Lee; Yong-Koo Park; Youn Wha Kim; Gou Young Kim; Kyu Yeoun Won; Sung-Jig Lim
Journal:  Clin Res Hepatol Gastroenterol       Date:  2015-10-23       Impact factor: 2.947

6.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

7.  Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway.

Authors:  Irina Daurkin; Evgeniy Eruslanov; Taryn Stoffs; George Q Perrin; Chester Algood; Scott M Gilbert; Charles J Rosser; Li-Ming Su; Johannes Vieweg; Sergei Kusmartsev
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

Review 8.  Improvement of different vaccine delivery systems for cancer therapy.

Authors:  Azam Bolhassani; Shima Safaiyan; Sima Rafati
Journal:  Mol Cancer       Date:  2011-01-07       Impact factor: 27.401

Review 9.  Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer.

Authors:  Thomas Powles; Brian Rini
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

10.  Macrophage activation and polarization: nomenclature and experimental guidelines.

Authors:  Peter J Murray; Judith E Allen; Subhra K Biswas; Edward A Fisher; Derek W Gilroy; Sergij Goerdt; Siamon Gordon; John A Hamilton; Lionel B Ivashkiv; Toby Lawrence; Massimo Locati; Alberto Mantovani; Fernando O Martinez; Jean-Louis Mege; David M Mosser; Gioacchino Natoli; Jeroen P Saeij; Joachim L Schultze; Kari Ann Shirey; Antonio Sica; Jill Suttles; Irina Udalova; Jo A van Ginderachter; Stefanie N Vogel; Thomas A Wynn
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

View more
  7 in total

1.  Hepcidin as a prognostic biomarker in clear cell renal cell carcinoma.

Authors:  Zijian Zhou; Jiajin Wu; Yuanyuan Yang; Peng Gao; Lujia Wang; Zhong Wu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Gene expression-based immune infiltration analyses of renal cancer and their associations with survival outcome.

Authors:  Lei Chen; Liang Yin; Zilong Qi; Jinmin Li; Xinning Wang; Kun Ma; Xiangyang Liu
Journal:  BMC Cancer       Date:  2021-05-24       Impact factor: 4.430

3.  Analysis of Ferroptosis-Related Gene Expression and Prognostic Factors of Renal Clear Cell Carcinoma Based on TCGA Database.

Authors:  Sijia Ma; Mingming Zhao; Jiao Fan; Meiying Chang; Zhiyu Pan; Ziyan Zhang; Shunxuan Xue; Qi Li; Yu Zhang
Journal:  Int J Gen Med       Date:  2021-09-22

4.  Identification of PLAUR-related ceRNA and immune prognostic signature for kidney renal clear cell carcinoma.

Authors:  Yu Wang; Zhuolun Sun; Shuo Lu; Xu Zhang; Chutian Xiao; Tengcheng Li; Jieying Wu
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

5.  miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma.

Authors:  Jinxiang Wang; Jie Jin; Yanling Liang; Yihe Zhang; Nisha Wu; Mingming Fan; Fangyin Zeng; Fan Deng
Journal:  Front Genet       Date:  2022-09-13       Impact factor: 4.772

6.  The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.

Authors:  Kadriye Bir Yücel; Emre Yekedüz; Serdar Karakaya; Deniz Tural; İsmail Ertürk; Cihan Erol; Özlem Ercelep; Nihan Şentürk Öztaş; Çağatay Arslan; Gökhan Uçar; Ahmet Küçükarda; Özlem Nuray Sever; Saadettin Kılıçkap; Orçun Can; Satı Coşkun Yazgan; Berna Öksüzoğlu; Nuri Karadurmuş; Mehmet Ali Şendur; Yüksel Ürün
Journal:  Sci Rep       Date:  2022-10-03       Impact factor: 4.996

7.  Distribution of CD8 T Cells and NK Cells in the Stroma in Relation to Recurrence or Metastasis of Nasopharyngeal Carcinoma.

Authors:  Yi Li; Hui Dong; Yudi Dong; Qiaoyuan Wu; Ni Jiang; Qing Luo; Fang Chen
Journal:  Cancer Manag Res       Date:  2022-09-27       Impact factor: 3.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.